Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
PDL-1 assay concordance

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.10.16
Views: 1998

Dr Jill Walker - AstraZeneca, UK

Dr Walker speaks with ecancertv at ESMO 2016 about the analytical consistency of four PDL-1 assays.

She describes results based on assaying samples from head and neck cancers, with three of four assays being tested reaching a high degree of result harmonisation.

Dr Marianne Ratcliffe spoke with ecancertv earlier in the year at AACR 2016 about PDL-1 assay concordance, and Dr Walker considers the advances on the data presented then, and wider adoption of immuno-oncology in the future.

PD-1 and PDL-1 expression was considered in multiple sites during ESMO 2016, including prostate cancer by Dr Julie Graff, melanoma by Dr Alexander Eggermont and lung cancer by Dr Martin Reck. 


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation